Clinical Trials Logo
  1. Home
  2. CNS Cancer
  3. NCT00588523

Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma

CNS Cancer Clinical Trial

Official title:
A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma

Clinical Trial Summary

The purpose of this study is to see how effective treatment of high doses of chemotherapy is for your tumor. We will also be looking at the side effects and risks of this treatment. You will receive very high doses of chemotherapy. High doses of chemotherapy can destroy tumor cells, but it can also destroy normal bone marrow cells. These cells produce white blood cells (which fight infection), red blood cells (which carry oxygen) and platelets (which allow your blood to clot). With too few of these cells there is a serious risk of infection and bleeding. Therefore, before treatment begins, we will collect some of your own blood cells, called peripheral blood progenitor cells (PBPCs). These cells help create new blood cells. The PBPCs are frozen and saved while you are being treated. Then at the end of treatment, your PBPCs are thawed and given back to you. These healthy PBPCs will replace the blood cells that the high dose chemotherapy destroys and allow your bone marrow to recover and produce blood cells. In a prior study we treated 69 patients in a similar way. More than half were able to avoid or delay brain radiation. This new study will use a different high dose chemotherapy regimen.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00588523
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Completed
Phase Phase 2
Start date September 2002
Completion date February 2, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT00589784 - Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Phase 2
Completed NCT00588640 - Study of D-Methadone in Patients With Chronic Pain Phase 1/Phase 2
Completed NCT00594633 - Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors Phase 1
Completed NCT00582608 - Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9 N/A
Recruiting NCT05142033 - Avera Cancer Sequencing and Analytics Protocol (ASAP)
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Completed NCT00599703 - Language Function in Patients With Brain Tumors N/A
Completed NCT00597246 - Imaging Brain Tumors With FACBC and Methionine N/A
Recruiting NCT06322342 - Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent Phase 2
Recruiting NCT05313191 - Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors N/A
Completed NCT00581815 - Spectroscopy With Surface Coils and Decoupling Phase 1
Active, not recruiting NCT04023669 - Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors Phase 1